// App-Quantinova.ai

3770 : Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Researchers

Presenter

  • Luigina Mollica

Principal Investigators

  • Lydia Roy

  • Aude Charbonnier

  • Caroline Dartigeas

  • Jean-Michel Cayuela

  • Lambert Busque

  • Mathieu Molimard

  • Joelle Guilhot

  • Francois Guilhot

  • Francois-Xavier Mahon

  • Stephane Bouchet

  • Agnes Guerci

  • Franck E Nicolini

  • Emmanuelle Chauzit

  • Pascale Cony-Makhoul

  • Valerie Coiteux

  • Martine Gardembas

  • Laurence Legros

Medical Centers

  • Institut Bergonie, Bordeaux, France

  • Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Canada

  • Laboratoire Hematopoese Leucemique et Cible Therapeutique, Inserm U1035, Universite Victor Segalen, Bordeaux, France

  • Hematology Department, CHU, Angers, France

  • Laboratoire Central -Hematologie, Hopital Saint-Louis, Paris, France

  • Hematology-Oncology Division, Maisonneuve-Rosemont Hospital, Universite de Montreal, Montreal, QC, Canada

  • Hopital Archet 2, Nice, France

  • Service Oncologie et Hematologie, CHU de Tours, Tours, France

  • Inserm CIC 1402, CHU de Poitiers, Poitiers, France

  • Service dHematologie et Oncologie, Hopital de Versailles, Universite Versailles Saint Quentin en Yvelines, Le Chesnay, France

  • Inserm U897, Universite de Bordeaux, Bordeaux, France

  • CHU de Poitiers et INSERM CIC 802, Poitiers University Hospital, Poitiers, France

  • CHU Poitiers, Poitiers, France

  • Hematology Department, Centre Hospitalier -Annecy, Pringy, France

  • Dermatology Department, CHRU Lille, Lille, France

  • CHU Nancy, Nancy, France

  • Departement de Pharmacologie, Universite de Bordeaux, Bordeaux, France

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Pavillon E Hematology Department, Hospital E. Herriot, Lyon, France

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Cluster of Differentiation 206

Drug/Treatment

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • Sprycel

Outcome

  • N/A

Study Design

  • randomized

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved